Upgrade to SI Premium - Free Trial

Oppenheimer on Nektar Therapeutics (NKTR): 'meaningful opportunities for biologics in AA'

April 1, 2026 9:57 AM
Oppenheimer analyst Jay Olson reiterated an Outperform rating and $140.00 price target on Nektar Therapeutics (NASDAQ: NKTR)The analyst commented, "Nektar ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments